口服XIa因子抑制剂Asundexian在急性心肌梗死后的2期剂量探索试验
这项多中心、随机、双盲、安慰剂对照2期试验纳入1601例近期急性心肌梗死患者,在阿司匹林联合P2Y12抑制剂基础上加用Asundexian 10、20、50 mg每日一次或安慰剂。结果显示Asundexian呈剂量依赖性抑制FXIa活性,50 mg抑制率>90%,汇总分析未显著增加出血,缺血事件发生率低,支持50 mg剂量进入更大样本试验。
要点
- Asundexian在急性心梗后联合双联抗血小板治疗呈剂量依赖性抑制FXIa。
- 50 mg每日一次使FXIa活性抑制>90%。
- 汇总Asundexian与安慰剂出血风险无显著差异,缺血事件率低。
核心结论
- 近期急性心梗患者中,Asundexian 10、20、50 mg加用阿司匹林联合P2Y12抑制剂呈剂量依赖性近完全抑制FXIa活性,未显著增加出血且缺血事件率低。
- 数据支持以50 mg每日一次剂量在充分把握度的急性心梗临床试验中进一步研究Asundexian。
研究设计与样本
- 多中心、2期、随机、安慰剂对照、双盲、平行组、剂量探索试验,纳入1601例近期急性心梗患者。
- 患者随机分配至口服Asundexian 10、20、50 mg或安慰剂每日一次,治疗6至12个月。
- 患者在合格心梗后5天内随机,并接受阿司匹林联合P2Y12抑制剂双联抗血小板治疗。
- 预设主要安全性结局为BARC 2、3或5型出血,汇总所有Asundexian剂量与安慰剂比较。
- 预设疗效结局为心血管死亡、心梗、卒中或支架血栓复合终点,汇总Asundexian 20和50 mg与安慰剂比较。
主要发现
- 中位年龄68岁,23%为女性,51%为ST段抬高型心梗,80%接受阿司匹林联合替格瑞洛或普拉格雷,99%在随机前接受经皮冠状动脉介入治疗。
- Asundexian引起剂量相关FXIa活性抑制,50 mg导致>90%抑制。
- 中位随访368天,主要安全性结局在Asundexian 10 mg、20 mg、50 mg和安慰剂组分别发生于30例(7.6%)、32例(8.1%)、42例(10.5%)和36例(9.0%);汇总Asundexian与安慰剂比较风险比0.98(90% CI 0.71-1.35)。
- 疗效结局在Asundexian 10 mg、20 mg、50 mg和安慰剂组分别发生于27例(6.8%)、24例(6.0%)、22例(5.5%)和22例(5.5%);汇总Asundexian 20和50 mg与安慰剂比较风险比1.05(90% CI 0.69-1.61)。
临床怎么用
- 近期急性心梗且接受双联抗血小板治疗的患者中,Asundexian 50 mg每日一次可近完全抑制FXIa活性且未显著增加出血。
- 该2期数据支持在充分把握度的临床试验中进一步评估Asundexian 50 mg每日一次用于急性心梗后二级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). METHODS: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition was assessed at 4 weeks. The prespecified main safety outcome was Bleeding Academic Research Consortium type 2, 3, or 5 bleeding comparing all pooled asundexian doses with placebo. The prespecified efficacy outcome was a composite of cardiovascular death, MI, stroke, or stent thrombosis comparing pooled asundexian 20 and 50 mg doses with placebo. RESULTS: The median age was 68 years, 23% of participants were women, 51% had ST-segment-elevation MI, 80% were treated with aspirin plus ticagrelor or prasugrel, and 99% underwent percutaneous coronary intervention before randomization. Asundexian caused dose-related inhibition of FXIa activity, with 50 mg resulting in >90% inhibition. Over a median follow-up of 368 days, the main safety outcome occurred in 30 (7.6%), 32 (8.1%), 42 (10.5%), and 36 (9.0%) patients receiving asundexian 10 mg, 20 mg, or 50 mg, or placebo, respectively (pooled asundexian versus placebo: hazard ratio, 0.98 [90% CI, 0.71-1.35]). The efficacy outcome occurred in 27 (6.8%), 24 (6.0%), 22 (5.5%), and 22 (5.5%) patients assigned asundexian 10 mg, 20 mg, or 50 mg, or placebo, respectively (pooled asundexian 20 and 50 mg versus placebo: hazard ratio, 1.05 [90% CI, 0.69-1.61]). CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients who experienced acute MI. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04304534; URL: https://www.clinicaltrialsregister.eu/ctr-search/search; Unique identifier: 2019-003244-79.
引用
- Rao, Kirsch, Bhatt, et al. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation. 2022. PMID: 36030390. doi:10.1161/CIRCULATIONAHA.122.061612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。